Alexion Pharmaceuticals, Inc. announced today that Japan's Ministry of Health, Labour and Welfare approved the Company's New Drug Application for the use of Strensiq A as a treatment for patients in Japan with hypophosphatasia , a life-threatening, ultra-rare metabolic disorder. Strensiq, a bone-targeted enzyme replacement therapy, is the first therapy approved in Japan for the treatment of patients with HPP.